Vetigenics, a Philadelphia, PA-based clinical-stage animal health biotechnology company, raised $6M in Seed funding.
Backers were not disclosed.
The company intends to use the funds to advance clinical-stage programs toward pivotal trials, accelerate preclinical candidates, and scale up operations and manufacturing.
Led by Adriann Sax, President, CEO and co-founder, and Nicola Mason, BVetMed, PhD, DACVIM, FRCVS, co-founder and clinical investigator, Vetigenics is a clinical-stage animal health biopharmaceutical company committed to advancing targeted antibody therapies for pets from a platform that provides unlimited therapeutic potential. Its proprietary CANIBODY™ technology improves solutions to develop superior antibodies proven effective in humans with cancer and chronic diseases but created specifically for pets. Its expertise in antibody discovery and development are also used by global animal health partners and the National Cancer Institute.
Two major trials using Vetigenics’ antibodies to treat canine cancer have reached key milestones:
- VGS-001 (anti-cCTLA4): The antibody therapy was combined with palliative radiation to treat oral melanoma in dogs. The trial is complete, and encouraging results are expected to be published in 2025.
- VGS-002 (anti-cPD1): The study using VGS-002 as monotherapy in dogs with urothelial carcinoma is nearing completion and promising results are anticipated later this year.
The company has also established a board of directors made up of prominent industry leaders to guide its continued growth:
- Chand Khanna, DVM, PhD, a leader in comparative oncology and translational medicine
- Stephen Lesser, JD, MBA, a seasoned strategic advisor in biotechnology and life sciences
- Caleb Frankel, VMD, an EMR pioneer and tech innovator in the veterinary space
- Adriann Sax, MBA, President, CEO and co- founder of Vetigenics.
FinSMEs
03/02/2025